Business
LivaNova to Present Autonomic Regulation Therapy Findings for Heart Failure During European Society of Cardiology Congress 2020
LONDON--(BUSINESS WIRE)-- LivaNova PLC (NASDAQ:LIVN) a market-leading medical technology and innovation company, today announced it will present a poster at
About this update from Livanova Plc
[{"type":"text","content":" LONDON--(BUSINESS WIRE)--\nLivaNova PLC (NASDAQ:LIVN) a market-leading medical technology and innovation company, today announced it will present a poster at the European Society of Cardiology (ESC) Congress 2020 on the potential for autonomic regulation therapy (ART) via vagus nerve stimulation to improve long-term cardiovascular function in patients with heart failure. The virtual Congress runs from Saturday, Aug. 29 through Tuesday, Sept. 1.\n\n\nIn a novel therapeutic approach, the LivaNova VITARIA® System delivers ART via mild electrical impulses applied to the right vagus nerve to increase parasympathetic activity in ways that improve regulation of cardiovascular function, including electrophysiological stability, in patients with advanced heart failure. The ANTHEM-HF clinical study (NCT01823887) reported improved baroreceptor sensitivity (heart rate turbulence or HRT), heart rate variability (rMSSD) and reduced cardiac electrical instability (T-wave alternans or TWA) after 12 months of chronic vagus nerve stimulation. However, it remained unknown whether these benefits persist beyond one year.\n\n\n“With more than 25 million people worldwide suffering from heart failure, it is crucial that we find improved methods to treat this complex syndrome,” said Bruce H. KenKnight, PhD and LivaNova Vice President of the Heart Failure Program. “In the ANTHEM-HF study, we evaluated HRT, rMSSD and TWA at six, 12, 24 and 36 months to assess the durability of therapeutic effects. We look forward to sharing the long-term results during ESC 2020.”\n\n\nIn lieu of traditional in-person presentations, ESC will publish all e-posters accepted for presentation on Friday, Aug. 28 at 7:30 a.m. London time. The following LivaNova poster will be shared:\n\n\n“Multi-Year Improvement in Autonomic Tone, Baroreceptor Sensitivity and Cardiac Electrical Stability Using Vagus Nerve Stimulation in Patients with HFrEF in the ANTHEM-HF Study”\nBruce D. Nearing, PhD, Inder S. Anand, MD, Imad Libbus, PhD, Lorenzo A. DiCarlo, MD, Bruce H. KenKnight, PhD and Richard L. Verrier, PhD, FACC\n\n\nThe VITARIA System received CE Mark approval in 2015 and has been approved by the U.S. Food and Drug Administration (FDA) to participate in the Breakthrough Technology Program. If approved by the FDA, it could be the first in its class for treating chronic heart failure. V...